Brought to you by 
Vigilant Biosciences brings in $5.5mm through Series B round
13 Mar 2015
Executive Summary
Cancer diagnostics company Vigilant Biosciences Inc. raised $5.5mm through its Series B round from White Owl Capital Partners, venVelo, the Florida Institute for the Commercialization of Public Research, and existing backers, along with private and angel life sciences investors. Funds will be put towards CE mark and FDA approval of OncAlert, an oral rinse that detects early-stage oral cancer.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vigilant Biosciences brings in $5.5mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice